KRISTEN HALEY: Open Payments
NPI 1710506944 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$357 in 18 payments from 10 companies in 2025. Trend: 2023 $64 · 2024 $751 · 2025 $357
Food & beverage: $357
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $78 |
| ABBVIE INC. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
Products named: VRAYLAR, REXULTI, AUSTEDO XR, FANAPT, CAPLYTA, Auvelity, UZEDY, SPRAVATO.
Industry payments across TX — which companies pay providers there.
